MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has secured U.S. Food and Drug Administration (FDA) approval for the commercial production of VASOSTRICT® (vasopressin injection, USP) at its newly constructed aseptic manufacturing facility in Indore, India. This state-of-the-art, 20,000-square-foot site marks a key milestone for Endo’s Injectable Solutions business.
“This is a significant milestone for Endo as we invest and innovate in our sterile injectables business,” said Scott Hirsch, Interim CEO of Endo. “The FDA approval of our newest manufacturing site demonstrates our commitment to meeting product demand and delivering quality medicines to patients.”
The Indore site, purpose-built for aseptic production of sterile injectable products, signals Endo’s expansion in this highly specialized field. The facility will initially manufacture medications in vial form, with future plans to produce sterile injectables in syringes.
This is the first U.S. FDA approval for the Indore facility. Endo has plans to seek additional product approvals for the site, with commercial production expected to ramp up in 2026. The increased capacity aims to meet growing demand while supporting Endo’s future growth in the sterile injectable market.
By investing in this advanced facility, Endo reinforces its innovation-driven approach to delivering critical medicines worldwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.